Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
基本信息
- 批准号:8186225
- 负责人:
- 金额:$ 34.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-11 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAnimal ModelAnimalsBMP2 geneBlood CirculationBone MarrowBone MatrixBone Morphogenetic ProteinsBone TransplantationCalvariaCholesterol HomeostasisCollagenDefectDevelopmentEffectivenessEmbryoErinaceidaeFamilyFibroblastsFractureFutureGene TargetingGoalsHealedHumanIn VitroInvestigationLigandsLiverMediatingMediator of activation proteinMesenchymalMesenchymal Stem CellsModelingMolecularMolecular Mechanisms of ActionMusNeonatalNuclearOrgan Culture TechniquesOsteogenesisParentsPathway interactionsPlayPropertyProteinsRat-1RattusReceptor ActivationReceptor SignalingRecombinantsRelative (related person)ReportingRoleSignal PathwaySignal TransductionSpeedSpinal FusionStromal CellsStructure-Activity RelationshipTestingTissuesanalogbonebone cellbone healingclinically relevantcomparative efficacycosthealingimmunogenicimprovedin vitro activityin vivoin vivo Modellipid biosynthesisnotch proteinnovelosteogenicosteoprogenitor cellreceptorresponsescaffoldsmall moleculesmoothened signaling pathwaytranscription factor
项目摘要
DESCRIPTION (provided by applicant): We have previously reported that specific endogenously produced small molecule oxysterols, formed in vivo as intermediaries of cholesterol metabolism, have potent osteogenic effects on multipotent mesenchymal stem cells (MSC) in vitro. We have shown that these effects are mediated through activation of the Hedgehog (Hh) signaling pathway, independent of Hh proteins. In addition, we have demonstrated that these oxysterols induce bone formation in neonatal mouse calvaria organ cultures, and bone healing in both a rat calvarial critical-sized defect model and a rat spinal fusion model in vivo. Thus, these oxysterols could potentially replace currently used expensive recombinant bone morphogenetic proteins (BMPs) and autogenous bone grafts for stimulation of local bone formation in non-healing fractures and critical bone defects. In addition, we have shown that when used in combination with BMPs, osteogenic oxysterols greatly reduce the concentration of BMPs required to induce effective osteogenesis in vitro. Accordingly, we have recently performed oxysterol structure activity relationship (SAR) studies that have resulted in the synthesis of a novel family of potent oxysterol analogues that possess osteogenic and anti-adipogenic activity equal or superior to the parent oxysterols. However, in addition to activating the Hh pathway, osteogenic oxysterols also activate liver X receptor (LXR) signaling whose role in osteogenesis is unclear and may promote oxysterol-induced osteogenesis by regulating targets of Notch signaling. Therefore, we hypothesize that osteogenic oxysterol analogues activate Hh and LXR signaling in osteoprogenitor cells and that both signaling pathways play an important role in osteogenic responses to oxysterols. To examine this hypothesis, we will pursue the following specific aims: 1) Elucidate the molecular signaling profile of osteogenic oxysterol analogues to determine the role and relative activation levels of Hh and LXR signaling in oxysterol-induced osteogenesis in vitro; 2) Examine the osteogenic activity of oxysterols and their mechanism of action in vivo for local administration using the rat spinal fusion and femoral defect models, while defining the optimal scaffold for local delivery and elucidating the role of Hh signaling in oxysterol effects in vivo; and 3) Examine the role of baseline and oxysterol-induced Hh pathway activity in BMP2-induced osteogenesis by determining whether Hh signaling through Gli transcription factors mediates the synergy between oxysterols and BMPs in stimulating osteogenesis in vitro and in vivo, and whether oxysterols may potentially improve the quality of the newly formed bone by inhibiting BMP2 stimulation of adipogenesis. These studies will provide important new information regarding the basic mechanisms regulating osteogenesis and the effects of oxysterols, as well as guidance for future investigations of oxysterols as a potential new class of osteoinductive agents for localized and perhaps systemic osteoregeneration.
PUBLIC HEALTH RELEVANCE: The studies proposed in this application will characterize a novel class of compounds that are potent stimulators of bone and bone cell formation, and will validate the ability of these molecules to stimulate bone healing alone and in combination with BMP2 in clinically relevant animal models. Results from these studies will provide important information for further development of future novel compounds that could be used for stimulating bone healing and strengthening in humans.
描述(由申请人提供):我们之前报道过特异性内源性小分子氧甾醇,作为体内胆固醇代谢的中介,在体外对多能间充质干细胞(MSC)具有强大的成骨作用。我们已经证明,这些作用是通过激活独立于Hh蛋白的Hedgehog (Hh)信号通路介导的。此外,我们已经证明这些氧化甾醇在新生小鼠颅骨器官培养中诱导骨形成,并在大鼠颅骨临界尺寸缺陷模型和大鼠脊柱融合模型中诱导骨愈合。因此,这些氧甾醇有可能取代目前使用的昂贵的重组骨形态发生蛋白(BMPs)和自体骨移植物来刺激未愈合骨折和严重骨缺损的局部骨形成。此外,我们已经证明,当与bmp联合使用时,成骨氧甾醇大大降低了体外诱导有效成骨所需的bmp浓度。因此,我们最近进行了氧甾醇结构活性关系(SAR)研究,合成了一种新的强效氧甾醇类似物家族,具有与母体氧甾醇相同或优于母体氧甾醇的成骨和抗脂肪活性。然而,除了激活Hh通路外,成骨氧甾醇还激活肝脏X受体(LXR)信号,其在成骨中的作用尚不清楚,可能通过调节Notch信号的靶点来促进氧甾醇诱导的成骨。因此,我们假设成骨氧甾醇类似物激活骨祖细胞中的Hh和LXR信号通路,并且这两种信号通路在对氧甾醇的成骨反应中起重要作用。为了验证这一假设,我们将追求以下具体目标:1)阐明成骨性氧甾醇类似物的分子信号谱,以确定Hh和LXR信号在体外氧甾醇诱导成骨中的作用和相对激活水平;2)利用大鼠脊柱融合术和股骨缺损模型,研究氧甾醇的成骨活性及其在体内局部给药的作用机制,同时确定局部给药的最佳支架,并阐明Hh信号在体内氧甾醇作用中的作用;3)通过确定通过Gli转录因子的Hh信号传导是否介导氧甾醇和bmp在体外和体内刺激成骨过程中的协同作用,以及氧甾醇是否可能通过抑制BMP2刺激脂肪生成来改善新生骨的质量,检验基线和氧甾醇诱导的Hh通路活性在bmp诱导成骨过程中的作用。这些研究将提供关于调控成骨的基本机制和氧甾醇作用的重要新信息,并为今后研究氧甾醇作为一种潜在的新类型的局部或全身性成骨诱导剂提供指导。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
FARHAD PARHAMI其他文献
FARHAD PARHAMI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('FARHAD PARHAMI', 18)}}的其他基金
Evaluation of anti-fibrotic and anti-inflammatory semi-synthetic oxysterol, Oxy210, as a therapeutic drug candidate for non-alcoholic steatohepatitis
抗纤维化和抗炎半合成氧甾醇 Oxy210 作为非酒精性脂肪性肝炎候选治疗药物的评价
- 批准号:
10697132 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Effect of a semi-synthetic oxysterol drug candidate, Oxy210, on atherosclerosis in a mouse model of NASH
半合成氧甾醇候选药物 Oxy210 对 NASH 小鼠模型动脉粥样硬化的影响
- 批准号:
10474926 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
An oxysterol drug candidate, Oxy210, for inhibition of pulmonary fibrosis through targeting hedgehog and TGFβ signaling
氧甾醇候选药物 Oxy210,通过靶向刺猬蛋白和 TGFβ 信号传导抑制肺纤维化
- 批准号:
10545973 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion
用于脊柱融合的成骨氧甾醇 (Oxy133) 的治疗开发
- 批准号:
10478295 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Therapeutic Development of Osteogenic Oxysterol, Oxy133, for Spine Fusion
用于脊柱融合的成骨氧甾醇 (Oxy133) 的治疗开发
- 批准号:
10256352 - 财政年份:2021
- 资助金额:
$ 34.65万 - 项目类别:
Inhibition of Liver Fibrosis by Oxysterol Drug Candidates in a Mouse Model of NASH
氧甾醇候选药物在 NASH 小鼠模型中抑制肝纤维化
- 批准号:
10076454 - 财政年份:2020
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8727972 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8890648 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8299488 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
Development of Osteogenic Oxysterols for Local Bone Formation
用于局部骨形成的成骨氧甾醇的开发
- 批准号:
8501384 - 财政年份:2011
- 资助金额:
$ 34.65万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 34.65万 - 项目类别:
Studentship